Stockholders’ Equity (Deficit) (Details) - USD ($)
|
|
|
3 Months Ended |
12 Months Ended |
Nov. 13, 2024 |
Aug. 24, 2024 |
Mar. 31, 2026 |
Mar. 31, 2025 |
Dec. 31, 2025 |
Dec. 31, 2024 |
| Stockholders’ Equity (Deficit) [Line Items] |
|
|
|
|
|
|
| Preferred stock, shares authorized (in Shares) |
|
|
5,000,000
|
|
5,000,000
|
|
| Private placements |
|
|
On
March 16, 2026, the Board of Directors approved a private placement offering of up to $1,000,000 in restricted shares of the Company’s
common stock at a price below market value, to remain open until the Company achieves a listing on the Nasdaq Stock Market. During the
three months ended March 31, 2026, the Company issued 100,000 shares of common stock at $2.00 per share for aggregate proceeds of $200,000
under this offering. No shares were issued under a private placement during the three months ended March 31, 2025
|
|
|
In June
2025, the Company commenced an additional private placement offering for up to 2,000,000 shares of the Company’s common stock at
a price of $1.00 - $1.49 per share, or an aggregate of $2,000,000. The aggregate offering amount may be increased by the Company in the
future. During the year ended December 31, 2025, the Company issued 1,494,700 shares of common stock for total proceeds of $1,834,970
under this offering
|
| Employee options |
|
|
During
the three months ended March 31, 2026, the Company granted options to purchase an aggregate of 200,000 shares of common stock to two
independent members of the Board of Directors pursuant to a Board resolution dated January 3, 2026. The options have an exercise price
of $3.99 per share, representing the closing market price on the grant date, vest over 24 months at a rate of 4,166 shares per month
commencing the first full month following the grant date, and are exercisable for five years from the grant date. The grant-date fair
value of each award was estimated using the Black-Scholes option pricing model with the following assumptions: stock price and exercise
price of $3.99; expected term of 5 years; annualized volatility of 113.18%; risk-free rate of 3.74%; and no dividend yield. The per-option
grant-date fair value was $3.24, resulting in aggregate grant-date fair value of $649 for both awards combined. No options were granted
during the three months ended March 31, 2025.
|
|
|
|
| Stock based compensation expense |
|
|
|
|
|
$ 1,165,151,000
|
| Unrecognized compensation expense from stock options |
|
|
$ 742,000
|
|
$ 367,500
|
|
| Common and preferred stock issued for cash and acquisition Share (in Shares) |
|
1,000,000
|
|
|
|
|
| Related party transaction amount |
|
$ 100
|
|
|
|
|
| Related party transaction par value (in Dollars per share) |
|
$ 0.0001
|
|
|
|
|
| Related-party demand advances |
|
$ 675,700
|
|
|
|
|
| Preferred stock, shares outstanding (in Shares) |
|
|
|
|
|
|
| Restated share transfer agreement |
|
|
|
|
On
June 2, 2025, the Company executed a Restated Share Transfer Agreement with Intrepid View Partners, LP, under which Spectral acquired
1,698,890 common shares of a global autonomous vehicle company (the “WAV Company”) for an aggregate purchase price of $16,988,900,
which will be paid via the issuance of 1,698,890 restricted shares of Spectral’s common stock.
|
|
| Common stock issued pursuant to private placement, Value |
|
|
|
|
$ 1,834,970
|
|
| Sale of common stock |
|
|
|
|
|
$ 150,040
|
| Issuance of common stock pursuant to business combination |
|
|
|
|
12,880,000
|
|
| Company no longer owes compensation |
|
|
|
|
675,500
|
|
| Consideration paid in Consulting Agreement |
|
|
|
|
307,500
|
|
| Consideration paid in Marketing Services Agreement |
|
|
|
|
4,420,000
|
|
| Share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures (in Shares) |
|
|
200,000
|
|
|
6,810,000
|
| Share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate |
|
|
|
|
|
203.49%
|
| Share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate |
|
|
|
|
|
3.50%
|
| Grant date fair value |
|
|
|
|
|
$ 3,345,600
|
| Selling, general and administrative expense |
|
|
|
|
$ 1,077,319
|
$ 1,165,151
|
| Share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period (in Shares) |
|
|
|
|
3,163,125
|
|
| Unrecognized compensation expense |
|
|
|
|
$ 930,000
|
|
| Series Quantum Preferred Stock [Member] |
|
|
|
|
|
|
| Stockholders’ Equity (Deficit) [Line Items] |
|
|
|
|
|
|
| Stock based compensation expense |
|
|
|
|
|
|
| Common and preferred stock issued for cash and acquisition Share (in Shares) |
|
|
|
|
|
1,000,000
|
| Common Stock [Member] |
|
|
|
|
|
|
| Stockholders’ Equity (Deficit) [Line Items] |
|
|
|
|
|
|
| Stock based compensation expense |
|
|
|
|
|
$ 200,000
|
| Common and preferred stock issued for cash and acquisition Share (in Shares) |
|
|
|
|
|
5,050,000
|
| Common stock issued pursuant to business combination, Shares (in Shares) |
|
|
|
|
8,000,000
|
|
| Settlement of advances |
|
|
|
|
During
the year ended December 31, 2024, the Company issued 3,563,043 shares of common stock in satisfaction of $81,950 in advances. On the
date of the agreement, the fair market value of the common stock per the Company’s closing stock price was $347,040 resulting in
an extinguishment of debt of $265,090
|
|
| NNN [Member] |
|
|
|
|
|
|
| Stockholders’ Equity (Deficit) [Line Items] |
|
|
|
|
|
|
| Proceeds from issuance of common stock |
|
|
|
|
|
$ 1,010,000
|
| NNN [Member] | Series Quantum Preferred Stock [Member] |
|
|
|
|
|
|
| Stockholders’ Equity (Deficit) [Line Items] |
|
|
|
|
|
|
| Common and preferred stock issued for cash and acquisition Share (in Shares) |
1,000,000
|
|
|
|
1,000,000
|
1,000,000
|
| NNN [Member] | Common Stock [Member] |
|
|
|
|
|
|
| Stockholders’ Equity (Deficit) [Line Items] |
|
|
|
|
|
|
| Common and preferred stock issued for cash and acquisition Share (in Shares) |
|
|
|
|
|
5,050,000
|
| Scandere OU [Member] |
|
|
|
|
|
|
| Stockholders’ Equity (Deficit) [Line Items] |
|
|
|
|
|
|
| Sale of common stock |
|
|
|
|
$ 194,800
|
|
| Scandere OU [Member] | Common Stock [Member] |
|
|
|
|
|
|
| Stockholders’ Equity (Deficit) [Line Items] |
|
|
|
|
|
|
| Sale of common stock (in Shares) |
|
|
|
|
2,000,000
|
|
| Equity Option [Member] |
|
|
|
|
|
|
| Stockholders’ Equity (Deficit) [Line Items] |
|
|
|
|
|
|
| Stock based compensation expense |
|
|
$ 275,000
|
$ 416,000
|
|
|
| Private Placement June 2024 [Member] |
|
|
|
|
|
|
| Stockholders’ Equity (Deficit) [Line Items] |
|
|
|
|
|
|
| Proceeds from issuance of common stock |
|
|
|
|
|
$ 1,010,000
|
| Minimum [Member] |
|
|
|
|
|
|
| Stockholders’ Equity (Deficit) [Line Items] |
|
|
|
|
|
|
| Shares issued, price per share (in Dollars per share) |
|
|
|
|
|
$ 0.43
|
| Share-based compensation arrangement by share-based payment award, fair value assumptions, exercise price (in Dollars per share) |
|
|
|
|
|
$ 0.5
|
| Share-based compensation arrangement by share-based payment award, fair value assumptions, expected term |
|
|
|
|
|
6 years
|
| Maximum [Member] |
|
|
|
|
|
|
| Stockholders’ Equity (Deficit) [Line Items] |
|
|
|
|
|
|
| Shares issued, price per share (in Dollars per share) |
|
|
|
|
|
$ 0.61
|
| Share-based compensation arrangement by share-based payment award, fair value assumptions, exercise price (in Dollars per share) |
|
|
|
|
|
$ 0.72
|
| Share-based compensation arrangement by share-based payment award, fair value assumptions, expected term |
|
|
|
|
|
7 years
|
| Series Quantum Preferred Stock [Member] |
|
|
|
|
|
|
| Stockholders’ Equity (Deficit) [Line Items] |
|
|
|
|
|
|
| Preferred stock, shares authorized (in Shares) |
|
|
2,000,000
|
|
2,000,000
|
|
| Preferred stock, shares outstanding (in Shares) |
|
|
0
|
|
0
|
1,000,000
|